BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30054102)

  • 21.
    Pandey R; Johnson N; Cooke L; Johnson B; Chen Y; Pandey M; Chandler J; Mahadevan D
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
    Best MG; Sol N; Kooi I; Tannous J; Westerman BA; Rustenburg F; Schellen P; Verschueren H; Post E; Koster J; Ylstra B; Ameziane N; Dorsman J; Smit EF; Verheul HM; Noske DP; Reijneveld JC; Nilsson RJA; Tannous BA; Wesseling P; Wurdinger T
    Cancer Cell; 2015 Nov; 28(5):666-676. PubMed ID: 26525104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical benefit for clinical sequencing using cancer panel testing.
    Nishimura S; Sugimoto A; Kushiyama S; Togano S; Kuroda K; Yamamoto Y; Yamauchi M; Sumi T; Kaneda H; Kawaguchi T; Kato M; Tagami M; Oebisu N; Hoshi M; Kimura K; Kubo S; Muguruma K; Takashima T; Ohira M; Yashiro M
    PLoS One; 2021; 16(2):e0247090. PubMed ID: 33635883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.
    Kelemen LE; Earp M; Fridley BL; Chenevix-Trench G; ; Fasching PA; Beckmann MW; Ekici AB; Hein A; Lambrechts D; Lambrechts S; Van Nieuwenhuysen E; Vergote I; Rossing MA; Doherty JA; Chang-Claude J; Behrens S; Moysich KB; Cannioto R; Lele S; Odunsi K; Goodman MT; Shvetsov YB; Thompson PJ; Wilkens LR; Dörk T; Antonenkova N; Bogdanova N; Hillemanns P; Runnebaum IB; du Bois A; Harter P; Heitz F; Schwaab I; Butzow R; Pelttari LM; Nevanlinna H; Modugno F; Edwards RP; Kelley JL; Ness RB; Karlan BY; Lester J; Orsulic S; Walsh C; Kjaer SK; Jensen A; Cunningham JM; Vierkant RA; Giles GG; Bruinsma F; Southey MC; Hildebrandt MAT; Liang D; Lu K; Wu X; Sellers TA; Levine DA; Schildkraut JM; Iversen ES; Terry KL; Cramer DW; Tworoger SS; Poole EM; Bandera EV; Olson SH; Orlow I; Vestrheim Thomsen LC; Bjorge L; Krakstad C; Tangen IL; Kiemeney LA; Aben KKH; Massuger LFAG; van Altena AM; Pejovic T; Bean Y; Kellar M; Cook LS; Le ND; Brooks-Wilson A; Gronwald J; Cybulski C; Jakubowska A; Lubiński J; Wentzensen N; Brinton LA; Lissowska J; Hogdall E; Engelholm SA; Hogdall C; Lundvall L; Nedergaard L; Pharoah PDP; Dicks E; Song H; Tyrer JP; McNeish I; Siddiqui N; Carty K; Glasspool R; Paul J; Campbell IG; Eccles D; Whittemore AS; McGuire V; Rothstein JH; Sieh W; Narod SA; Phelan CM; McLaughlin JR; Risch HA; Anton-Culver H; Ziogas A; Menon U; Gayther SA; Gentry-Maharaj A; Ramus SJ; Wu AH; Pearce CL; Lee AW; Pike MC; Kupryjanczyk J; Podgorska A; Plisiecka-Halasa J; Sawicki W; Goode EL; Berchuck A;
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30134598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
    Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
    ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.
    Yang SR; Chang JC; Leduc C; Tan KS; Dogan S; Benayed R; Borsu L; Offin M; Drilon A; Travis WD; Arcila ME; Ladanyi M; Rekhtman N
    J Thorac Oncol; 2021 Jul; 16(7):1188-1199. PubMed ID: 33839364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical Loss of DPC4 in Tumors With Mucinous Differentiation Arising in or Involving the Gynecologic Tract.
    Kwon DH; Malpica A; Zaleski M; Euscher ED; Ramalingam P
    Int J Gynecol Pathol; 2021 Nov; 40(6):523-532. PubMed ID: 33405429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Molecular Profiling and Clinicopathological Characteristics of Gastric-Type Mucinous Carcinoma of the Uterine Cervix in Japanese Women.
    Nasu H; Nishio S; Park J; Tasaki K; Terada A; Tsuda N; Kawano K; Kojiro-Sanada S; Akiba J; Ushijima K
    Kurume Med J; 2024 May; 69(3.4):237-249. PubMed ID: 38369337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.
    Stella GM; Benvenuti S; Gentile A; Comoglio PM
    EBioMedicine; 2017 Oct; 24():34-42. PubMed ID: 29037604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
    Liu J; Westin SN
    Gynecol Oncol; 2016 Apr; 141(1):65-71. PubMed ID: 27016231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
    Kim YN; Chung YS; Park E; Lee ST; Lee JY
    Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and genomic landscape of RAS mutations in gynecologic cancers.
    Son J; Zhang Y; Lin H; Mirallas O; Alvarez Ballesteros P; Nardo M; Clark N; Hillman RT; Campbell E; Holla V; Johnson AM; Biter AB; Yuan Y; Cobb LP; Gershenson DM; Jazaeri AA; Lu KH; Soliman PT; Westin SN; Euscher ED; Lawson BC; Yang RK; Meric-Bernstam F; Hong DS
    Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiles of brain metastases: Prioritization of therapeutic targets.
    Ferguson SD; Zheng S; Xiu J; Zhou S; Khasraw M; Brastianos PK; Kesari S; Hu J; Rudnick J; Salacz ME; Piccioni D; Huang S; Davies MA; Glitza IC; Heymach JV; Zhang J; Ibrahim NK; DeGroot JF; McCarty J; O'Brien BJ; Sawaya R; Verhaak RGW; Reddy SK; Priebe W; Gatalica Z; Spetzler D; Heimberger AB
    Int J Cancer; 2018 Dec; 143(11):3019-3026. PubMed ID: 29923182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
    Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
    Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
    Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
    Huey RW; Shah AT; Reddi HV; Dasari P; Topham JT; Hwang H; Dhillon N; Willett A; Smaglo BG; Estrella JS; Rashid A; Matamoros A; Overman MJ; Choquette L; Omerza G; Kelly K; Wang X; Loree JM; Rueter J; Varadhachary GR; Raghav K
    J Natl Cancer Inst; 2023 Aug; 115(8):994-997. PubMed ID: 37202363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
    Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
    Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.
    Michuda J; Breschi A; Kapilivsky J; Manghnani K; McCarter C; Hockenberry AJ; Mineo B; Igartua C; Dudley JT; Stumpe MC; Beaubier N; Shirazi M; Jones R; Morency E; Blackwell K; Guinney J; Beauchamp KA; Taxter T
    Mol Diagn Ther; 2023 Jul; 27(4):499-511. PubMed ID: 37099070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.